This Article Full Text Full Text (PDF) All Versions of this Article: 25/2/436    most recent 01.ATV.0000152613.83243.12v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raffai, R. L. Articles by Weisgraber, K. H. Search for Related Content PubMed PubMed Citation Articles by Raffai, R. L. Articles by Weisgraber, K. H. Related Collections Animal models of human disease Genetically altered mice Lipid and lipoprotein metabolism Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:436.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Apolipoprotein E Promotes the Regression of Atherosclerosis Independently of Lowering Plasma Cholesterol Levels

Robert L. Raffai; Samuel M. Loeb; Karl H. Weisgraber

From the Division of Vascular Surgery and the Pacific Vascular Research Laboratories, Department of Surgery (R.L.R.), and the Department of Pathology and Cardiovascular Research Institute (K.H.W.), University of California, San Francisco, and the San Francisco Veterans Administration Medical Research Center (R.L.R.); and the Gladstone Institutes of Cardiovascular Disease and Neurological Disease (R.L.R., S.M.L., K.H.W.), San Francisco, California.

Correspondence to Robert L. Raffai, PhD, Division of Vascular Surgery, Department of Surgery, San Francisco Veterans Administration Medical Center, 4150 Clement St (112G), San Francisco, CA 94121. E-mail raffair{at}surgery.ucsf.edu

Objective— The mechanisms by which apolipoprotein E (apoE) can promote the regression of atherosclerosis are not well understood. This study examined whether apoE can promote atherosclerosis regression independently of lowering plasma cholesterol levels.

Methods and Results— We studied hypomorphic apoE mice (Apoe^h/h), which express an apoE4-like form of mouse apoE at 2% to 5% of normal levels in plasma and are normolipidemic. After 18 weeks of diet-induced hypercholesterolemia, which resulted in advanced aortic atherosclerotic lesions composed of a lipid-rich layer of foam cells covering a fibrotic core, 2 groups of mice were fed a chow diet for 16 weeks. One group continued to express low levels of apoE; the other was induced to express physiological levels of plasma apoE by Cre-mediated recombination of the hypomorphic Apoe allele. In both groups, plasma cholesterol levels fell rapidly to similar levels, and histological analysis at 16 weeks revealed elimination of the foam-cell layer. However, physiological levels of plasma apoE also enhanced the removal of neutral lipids from the fibrotic cores.

Conclusion— These findings demonstrate for the first time that apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels.

Using Apoe^h/hMx1-Cre mice we have begun to address apolipoprotein E–mediated mechanisms of atherosclerosis regression. We report the existence of a cholesterol-independent role of apolipoprotein E in atherosclerosis regression. This mechanism is critical for lipid removal from the fibrotic component of the plaque but not from the foam cell–rich layer beneath the endothelium.

Key Words: apoE • lipoprotein • atherosclerosis • regression • foam cell

Related Article:

Apolipoprotein E and Atherosclerosis: Beyond Lipid Effect

Jean Davignon
Arterioscler Thromb Vasc Biol 2005 25: 267-269. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				G. S. Getz and C. A. Reardon Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall J. Lipid Res., April 1, 2009; 50(Supplement): S156 - S161. [Abstract] [Full Text] [PDF]

				S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]

				A. E. Mullick, A. F. Powers, R. S. Kota, S. D. Tetali, J. P. Eiserich, and J. C. Rutledge Apolipoprotein E3- and Nitric Oxide-Dependent Modulation of Endothelial Cell Inflammatory Responses Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 339 - 345. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				E. D. MacDougall, F. Kramer, P. Polinsky, S. Barnhart, B. Askari, F. Johansson, R. Varon, M. E. Rosenfeld, K. Oka, L. Chan, et al. Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Combined with a Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice Am. J. Pathol., June 1, 2006; 168(6): 2064 - 2073. [Abstract] [Full Text] [PDF]

				G. S. Getz and C. A. Reardon Diet and Murine Atherosclerosis Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 242 - 249. [Abstract] [Full Text] [PDF]

				J. Ruiz, D. Kouiavskaia, M. Migliorini, S. Robinson, E. L. Saenko, N. Gorlatova, D. Li, D. Lawrence, B. T. Hyman, K. H. Weisgraber, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor J. Lipid Res., August 1, 2005; 46(8): 1721 - 1731. [Abstract] [Full Text] [PDF]

				J. Davignon Apolipoprotein E and Atherosclerosis: Beyond Lipid Effect Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 267 - 269. [Full Text] [PDF]